Laure-Anne Teuwen

7PUBLICATIONS
51CO-AUTHORS
Medical biotechnology not elsewhere classifiedPredictive and prognostic markersCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 31, 2026
Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

Laure-Anne Teuwen, Rachel P Riechelmann, Bishal Gyawali

|Sep 08, 2025
Success in oncology phase 3 trials: a small P value or patient value.

Laure-Anne Teuwen, Gregory R Pond, Bishal Gyawali

|Feb 27, 2025
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022.

Sofie Seghers, Pablo Mandó, Marc Eid

|Oct 03, 2024
Intersectionality Between Country, Gender and Funding in Authorship for Phase III Trials Presented at the ASCO Annual Meeting 2022.

Laure-Anne Teuwen, Joanna Young, Saleh Alessy

|Aug 08, 2024
Time to Update-Requesting Inclusive Submission Categories for Oncology Research.

Laure-Anne Teuwen, Zain Ahmad, Eva Segelov

|Jun 01, 2024
Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study.

Khalid El Bairi, Salma Najem, Arman Reza Chowdhury

Pageof 2

Frequent Collaborators

3 joint publications

Eva Segelov

3 joint publications

Hans Prenen

2 joint publications

Bishal Gyawali

2 joint publications

Joanna Young